Abstract
Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.
| Original language | English |
|---|---|
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 58 |
| Issue number | SUPPL. |
| DOIs | |
| Publication status | Published - Nov 2006 |
Fingerprint
Keywords
- EGFR
- Erlotinib
- Gefitinib
- KRAS
- Methylation
- NSCLC
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
The impact and role of EGFR gene mutation on non-small cell lung cancer. / Toyooka, Shinichi; Sou, Junichi; Shigematsu, Hisayuki; Aoe, Motoi; Date, Hiroshi.
In: Cancer Chemotherapy and Pharmacology, Vol. 58, No. SUPPL., 11.2006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The impact and role of EGFR gene mutation on non-small cell lung cancer
AU - Toyooka, Shinichi
AU - Sou, Junichi
AU - Shigematsu, Hisayuki
AU - Aoe, Motoi
AU - Date, Hiroshi
PY - 2006/11
Y1 - 2006/11
N2 - Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.
AB - Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.
KW - EGFR
KW - Erlotinib
KW - Gefitinib
KW - KRAS
KW - Methylation
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=33845235061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845235061&partnerID=8YFLogxK
U2 - 10.1007/s00280-006-0312-8
DO - 10.1007/s00280-006-0312-8
M3 - Article
AN - SCOPUS:33845235061
VL - 58
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - SUPPL.
ER -